Advertisement

Pharmaceutisch weekblad

, Volume 3, Issue 1, pp 1437–1442 | Cite as

Het farmacologisch profiel van de neuroleptica

  • C. J. E. Niemegeers
Voordrachten
  • 17 Downloads

Abstract

A survey comparing the animal pharmacology of neuroleptics is given. The tests discussed and mutually assessed are for the rat: antagonism of the effects induced by apomorphine, amphetamine, tryptamine, norepinephrine, substance 48/80 and eserine; inhibition of conditioned reactions and intracranial self-stimulation; induction of catalepsy and palpebral ptosis, delaying of oestrus and the acute toxicity. In the dog the tests performed are the antagonism of the emetic effect of apomorphine and the inhibition of conditioned reactions.

Taken as a whole the results are indicative of the clinical profile to be expected for a particular neuroleptic. This profile relates to the therapeutic possibilities, as well as wanted and unwanted secondary reactions and side effects, dosage and duration of action.

Samenvatting

Een vergelijkend dierfarmacologisch overzicht van de neuroleptica wordt gegeven. Verschillende onderzoekingen bij de rat en de hond worden besproken en onderling geëvalueerd. Het geheel geeft een indicatie van het te verwachten klinisch profiel van een neurolepticum, zowel wat betreft de therapeutische mogelijkheden als de bijkomende gewenste en ongewenste neveneffecten en bijwerkingen, dosering en werkingsduur.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatuur

  1. 1.
    Anden, N.E., A. Rubenson, K. Fuxe enT. Hökfelt (1967)J. Pharm. Pharmacol., 19, 627.CrossRefPubMedGoogle Scholar
  2. 2.
    Ansoms, C., G. de Backer-Dierick enJ.L.T.M. Vereecken (1977)Acta Psychiat. Neurol. Scand. 55, 116.CrossRefGoogle Scholar
  3. 3.
    Carlsson, A., enM. Lindqvist (1963)Acta Pharmacol. Toxicol. 20, 10.Google Scholar
  4. 4.
    Clineschmidt, B.V., enV.J. Lotti (1973)Brit. J. Pharmacol. 50, 311.CrossRefGoogle Scholar
  5. 5.
    Colpaert, F.C., W.F.M. Van Bever enJ.E. Leysen (1976) In:International Review of Neurobiology, Vol. 19 (Pfeiffer C.C., enJ.R. Smythies, Eds.). Academic Press, Londen, 225.CrossRefGoogle Scholar
  6. 6.
    Colpaert, F.C., H. Lal, C.J.E. Niemegeers enP.A.J. Janssen (1975)Life Sci. 16, 705.CrossRefPubMedGoogle Scholar
  7. 7.
    Colpaert, F.C., C.J.E. Niemegeers enP.A.J. Janssen (1977)Psychopharmacologia 53, 169.CrossRefGoogle Scholar
  8. 8.
    Deberdt, R. (1976)Acta Psychiat. Belg. 76, 157.Google Scholar
  9. 9.
    Ernst, A.M. (1967)Psychopharmacologia 10, 316.CrossRefPubMedGoogle Scholar
  10. 10.
    Ernst, A.M., enP.G. Smelik (1966)Experientia 22, 837.CrossRefPubMedGoogle Scholar
  11. 11.
    Fog, R. (1969)Psychopharmacologia 14, 299.CrossRefPubMedGoogle Scholar
  12. 12.
    Frantz, A.G. (1978)Psychologie Med. 298, 201.Google Scholar
  13. 13.
    Janssen, P.A.J. (1978)International Congress Series 9. Excerpta Medica, Amsterdam, 107.Google Scholar
  14. 14.
    Janssen, P.A.J., enC.J.E. Niemegeers (1961)Arzneimittel- Forsch. 11, 1037.Google Scholar
  15. 15.
    Janssen, P.A.J., C.J.E. Niemegeers enJ.G.M. Dony (1963)Arzneimittel-Forsch. 13, 401.Google Scholar
  16. 16.
    Janssen, P.A.J., C.J.E. Niemegeers enA.H.M. Jageneau (1960)Arzneimittel-Forsch. 10, 1003.Google Scholar
  17. 17.
    Janssen, P.A.J., C.J.E. Niemegeers enK.H.L. Schellekens (1965)Arzneimittel-Forsch. 15, 104.Google Scholar
  18. 18.
    Janssen, P.A.J., C.J.E. Niemegeers enK.H.L. Schellekens (1965)Arzneimittel-Forsch. 15, 1196.Google Scholar
  19. 19.
    Janssen, P.A.J., C.J.E. Niemegeers enK.H.L. Schellekens (1966)Arzneimittel-Forsch. 16, 339.Google Scholar
  20. 20.
    Janssen, P.A.J., C.J.E. Niemegeers, K.H.L. Schellekens enF.M. Lenaerts (1967)Arzneimittel-Forsch. 17, 841.Google Scholar
  21. 21.
    Janssen, P.A.J., C.J.E. Niemegeers, K.H.L. Schellekens, A. Dresse, F.M. Lenaerts, A. Pinchard, W.K.A. Schaper, J.M. Van Nueten enF.J. Verbruggen (1968)Arzneimittel-Forsch. 18, 261.Google Scholar
  22. 22.
    Janssen, P.A.J., C.J.E. Niemegeers, K.H.L. Schellekens, F.M. Lenaerts, F.J. Verbruggen, J.M. Van Nueten enW.K.A. Schaper (1970)Eur. J. Pharmacol. 11, 139.CrossRefPubMedGoogle Scholar
  23. 23.
    Maerz, J.E. (1975)Proc. Roy. Soc. Med. 69, Supplement 1, 1.Google Scholar
  24. 24.
    Marsboom, R. (1978)Int. Pharmakopsychiat. 13, Supplement 1, 3.Google Scholar
  25. 25.
    Niemegeers, C.J.E. (1962)Intern. J. Neuropharmacol. Google Scholar
  26. 26.
    Niemegeers, C.J.E. (1974) In:Industrial Pharmacology 1.Neuroleptics (Fielding, S., enH. Lal, Eds.). Futura Publishing Co., New York, 285–305.Google Scholar
  27. 27.
    Niemegeers, C.J.E., F. Awouters, J.M. van Nueten, P.A.J. Janssen enS. De Nollin (1978)Arch. Intern. Pharmacodyn. 234, 164–176.Google Scholar
  28. 28.
    Niemegeers, C.J.E., enP.A.J. Janssen (1960)J. Pharm. Pharmacol. 12, 744.CrossRefPubMedGoogle Scholar
  29. 29.
    Niemegeers, C.J.E., enP.A.J. Janssen (1978)Arch. Intern. Pharmacodyn. 236, 43.Google Scholar
  30. 30.
    Niemegeers, C.J.E., enP.A.J. Janssen (1979)Life Sci. 24, 2201.CrossRefPubMedGoogle Scholar
  31. 31.
    Niemegeers, C.J.E., A.J. Reyntjens, J.M. Van Nueten, P.M. Laduron, J. Heykants, K.H.L. Schellekens, R. Marsboom, A. Jageneau, A. Broeckaert enP.A.J. Janssen (1978)Arzneimittel-Forsch. 28, 1194.Google Scholar
  32. 32.
    Niemegeers, C.J.E., F.J. Verbruggen enP.A.J. Janssen (1969)Psychopharmacologia 16, 161.CrossRefPubMedGoogle Scholar
  33. 33.
    Niemegeers, C.J.E., F.J. Verbruggen enP.A.J. Janssen (1969)Psychopharmacologia 16, 175.CrossRefPubMedGoogle Scholar
  34. 34.
    Niemegeers, C.J.E., F.J. Verbruggen enP.A.J. Janssen (1970)Psychopharmacologia 17, 151.CrossRefPubMedGoogle Scholar
  35. 35.
    Niemegeers, C.J.E., F.J. Verbruggen enP.A.J. Janssen (1970)Psychopharmacologia 18, 249.CrossRefPubMedGoogle Scholar
  36. 36.
    Niemegeers, C.J.E., F.J. Verbruggen, A. Wauquier enP.A.J. Janssen (1972)Psychopharmacologia 25, 22.CrossRefPubMedGoogle Scholar
  37. 37.
    Niemegeers, C.J.E., K.H.L. Schellekens enP.A.J. Janssen (1981)Arch. Intern. Pharmacodyn. 244, 130.Google Scholar
  38. 38.
    Shome, B., enA.F. Parlow (1974)J. Crin. Endocrinol. Metab. 45, 1112.CrossRefGoogle Scholar
  39. 39.
    Singh, M.M., enJ.M. Smith (1973)J. Nervous Mental Disease 157, 50.CrossRefGoogle Scholar
  40. 40.
    Singh, M.M., enS.R. Kay (1975)J. Nervous Mental Disease 160, 258.CrossRefGoogle Scholar
  41. 41.
    Squelart, P., enJ. Saravia (1977)Acta Psychiat. Belg. 77, 284.Google Scholar
  42. 42.
    Tedeschi, D.M., R.E. Tedeschi enE.J. Fellows (1959)J. Pharmacol. Exp. Therap. 126, 223.Google Scholar
  43. 43.
    Tedeschi, D.M., R.E. Tedeschi enE.J. Fellows (1961)Arch. Intern. Pharmacodyn. 132, 172.Google Scholar
  44. 44.
    Rossum, J.M. Van, enJ.A.Th.M. Hurkmans (1964)J. Neuropharmacol. 3, 227.CrossRefGoogle Scholar
  45. 45.
    Wauquier, A. (1976)The influence of psychoactive drugs on brain self-stimulation behaviour. Proefschrift, Nijmegen, 258.Google Scholar
  46. 46.
    Wauquier, A., enC.J.E. Niemegeers (1972)Psychopharmacologia 27, 191.CrossRefPubMedGoogle Scholar
  47. 47.
    Wauquier, A., enC.J.E. Niemegeers (1975)Arch. Intern. Pharmacodyn. 217, 280.Google Scholar
  48. 48.
    Wauquier, A., C.J.E. Niemegeers enH. Lal (1976)Drugs and central synoptic transmission. The MacMillan Press Ltd., Londen, 201.CrossRefGoogle Scholar
  49. 49.
    Wauquier, A., C.J.E. Niemegeers enH.A. Geivers (1972)Psychopharmacologia 23, 238.CrossRefPubMedGoogle Scholar
  50. 50.
    Weisman, A. (1975)Eur. J. Pharmacol 33, 267.CrossRefGoogle Scholar
  51. 51.
    Woggon, B. (1977)Acta Psychiat. Belg. 78, 155.Google Scholar

Copyright information

© Bohn, Scheltema & Holkema 1981

Authors and Affiliations

  • C. J. E. Niemegeers
    • 1
  1. 1.Janssen PharmaceuticaResearch LaboratoriaBeerseBelgië

Personalised recommendations